Cic edizioni internazionali
Functional Neurology

Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey

Original Article, 253 - 258
doi: 10.11138/FNeur/2013.28.4.253
Tag this article
Abstract
Enhanced HTML Full text PDF
The aim of this survey was to provide an overview of important issues relating to therapeutic strategies based on botulinum toxin type A injection for the treatment of patients with neurological disorders.
Two hundred and ten physicians from neurology and neurorehabilitation units in Italian hospitals answered a questionnaire exploring some clinical aspects of the use of botulinum toxin type A in patients with spasticity/dystonia. 66% of the physicians treated patients with dystonia, 80% treated adults with spasticity, and 35% treated children with cerebral palsy.
Palpation with no instrumental guidance was the injection technique most commonly used for treating patients with dystonia, spasticity and cerebral palsy; 57% of the physicians evaluated patients instrumentally before toxin injection, while 45% assessed postinjection improvements by instrumental means; 78% of the physicians prescribed (when appropriate) rehabilitation procedures after toxin injection. Our results seem to show that the routine use of botulinum toxin in clinics is far from standardized.

Vol. XXXIII (No. 1) 2018 January/March

  1. Mechanical thrombectomy for acute ischemic stroke: the therapeutic window is larger but still “time is brain»
    Zivelonghi C., Tamburin S.
    doi: 10.11138/FNeur/2018.33.1.005
  2. Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal
    Ferrari A., Manca M., Tugnoli V., Alberto L.
    doi: 10.11138/FNeur/2018.33.1.007
  3. Multicentre registry of brain-injured patients with disorder of consciousness: rationale and preliminary data
    Pascarella A., Fiorenza S., Masotta O., Tibollo V., Vella D., Nardone A. M., Rossi M., Volanti P., Madonia F., Castronovo G., De Cicco D., Guarnaschelli C., Achilli M.P., Chiapparino C., Angelillo M.T., Tommasi M.A., Pisano F., Grioni G., Vezzadini G., Ferriero G., Salvaderi S., Bellazzi R., Estraneo A.
    doi: 10.11138/FNeur/2018.33.1.019
  4. Apathy in Parkinson’s disease: differences between caregiver’s report and self-evaluation
    Valentino V., Iavarone A., Amboni M., Moschiano F., Picillo M., Petretta V., Cicarelli G.
    doi: 10.11138/FNeur/2018.33.1.031
  5. Management of spasticity with onabotulinumtoxinA: practical guidance based on the italian real-life post-stroke spasticity survey
    Sandrini G., Baricich A., Cisari C., Paolucci S., Smania N., Picelli A.
    doi: 10.11138/FNeur/2018.33.1.037
  6. A role for accelerometry in the differential diagnosis of tremor syndromes
    Bove F., Di Lazzaro G., Mulas D., Cocciolillo F., Di Giuda D., Bentivoglio A.R.
    doi: 10.11138/FNeur/2018.33.1.045
  7. Effectiveness of a digital platform for sharing knowledge on headache management: a two-year experience
    Raieli V., Correnti E., Sandullo A., Romano M., Marchese F., Loiacono C., Brighina F.
    doi: 10.11138/FNeur/2018.33.1.051
  8. If you want to understand what it really means to live with cluster headache, imagine... fostering empathy through European patients’ own stories of their experiences
    Rossi P., Little P., De La Torre E.R., Palmaro A.
    doi: 10.11138/FNeur/2018.33.1.057
Last Viewed articles: la lista degli ultimi x visitati.
  1. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey
    Smania N., Colosimo C., Bentivoglio A.R., Sandrini G., Picelli A.
    doi: 10.11138/FNeur/2013.28.4.253
credits